TCGA-DK-A3IQ-01A-31R-A32Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.70696452
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.520
- HEDGEHOG_SIGNALING+0.500
- UV_RESPONSE_DN+0.500
- MYOGENESIS+0.480
- APICAL_JUNCTION+0.440
- COAGULATION+0.430
- APICAL_SURFACE+0.310
- TGF_BETA_SIGNALING+0.300
- WNT_BETA_CATENIN_SIGNALING+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.750
- MYC_TARGETS_V1-0.700
- E2F_TARGETS-0.680
- OXIDATIVE_PHOSPHORYLATION-0.590
- G2M_CHECKPOINT-0.580
- INTERFERON_ALPHA_RESPONSE-0.510
- MTORC1_SIGNALING-0.470
- DNA_REPAIR-0.440
- FATTY_ACID_METABOLISM-0.410
- INTERFERON_GAMMA_RESPONSE-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296795 | — | — | 0.958 |
| 2 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.956 |
| 3 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.941 |
| 4 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.939 |
| 5 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.921 |
| 6 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.916 |
| 7 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.914 |
| 8 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.911 |
| 9 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.910 |
| 10 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| MYOGENESIS | 0.480 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |